PATENT CLAIM ANALYSIS

Application Number: 15976012
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["544", "280000"]

Abstract:
The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for Hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases. Preferably the autoimmune disease is multiple sclerosis.

Claim (Index 16):
The method of  claim 13 , wherein the molecule is not a substrate for HPRT and lowers interferon gamma production in the mammalian cell.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 93.0
- Lexical Diversity: 1.64583
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15087807', '15087811', '15539519', '13256345', '15751782']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7127830203392618
- 35 USC 102 Novelty (BERT): 0.5008016678540372
- Combined Prediction Score: 0.6915848850907393
- Mean Citation Score: 163.07404
- Max Citation Score: 166.72618
- Similarity Product: 101.07006283035992

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test